Gina Kolata shares "a cautionary tale" about a man who received stem cell therapy at a Mexican clinic hoping to improve his recovery from stroke only to end up with an aggressive, vascular mass growing on his spine -- a growth triggered by donor cells. (The New York Times)
FDA approved changes in the REMS for vigabatrin in refractory complex partial seizures citing "benefits of Sabril outweigh the risks of vision loss and of suicidal thoughts and behaviors."
Even cheap meals appear to be linked to increased physician prescriptions for branded drugs. (JAMA)
Is a cash-based practice the right move for you? Works for this practice. (KevinMD)
Can big data prevent ER frequent flyers? (Kaiser Health News)
"Epidemic," is how the U.N. describes the surge to 20-year highs in American heroin use. (Reuters)
The future of drug testing? Testing therapeutics on a piece of you: Organoids and "personalized blobs." (The Atlantic)
Here's what the first year of life is like for children with Zika-caused microcephaly and their families. (BBC)
Life after death discovered ... at least in mice and zebrafish genes. (New Scientist)
How a small town physician practice and counselor worked together to help residents treat opioid addiction. (NPR)
Flesh eating bacteria devours a leg and a "brain-eating amoeba" kills a young woman. (Star Telegram, KTLA)
Pharmacists join docs in call for end of direct to consumer pharmaceutical advertising. (Becker's Hospital Review)
"Not just a young person's problem," said addiction researcher on opioid prescriptions to some 12 million Medicare patients in 2015. (STAT)
Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.
Morning Break: Stem Cell Tourism; What a Free Lunch Buys; DTC Ads Panned
Aucun commentaire:
Enregistrer un commentaire